'Lifechanging' migraine pill which slashes attacks by half set to be available in months
Millions of migraine sufferers could soon benefit from a new drug which has been found to reduce attacks by half.
Taken as a daily pill, trials of atogepant revealed it cut migraines from an average of eight to four a month double the success of current tablets.
The drug has been licensed by the Medicines and Healthcare products Regulatory Agency and experts predict it will soon be available to patients, pending a green light from the National Institute for Health and Care Excellence.
Known as a CGRP inhibitor, it works by blocking the effect of calcitonin gene-related peptide a protein known to trigger migraines.